Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
French drugmaker Sanofi agrees to purchase U.S. vaccines company Dynavax Technologies for $2.2 billion, gaining access to hepatitis B vaccine and experimental shingles shot.
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
Regeneron Pharmaceuticals exceeds Q3 2025 expectations with $3.75B revenue, driven by blockbuster eczema drug Dupixent and cancer treatment Libtayo, despite Eylea competition challenges.